dossier,guideline,type of study ,pdf link,"Endpoints: Observations: Clinical observation: changes in skin, fur, eyes, mucous membranes",Endpoints: Observations: Clinical observation: changes in the respiratory system,Endpoints: Observations: Clinical observation: changes in the circulatory system,Endpoints: Observations: Clinical observation: changes in the nervous system,Endpoints: Observations: Clinical observation: changes in somatomotor activity and behaviour patterns,Endpoints: Observations: Clinical observation: tremors,Endpoints: Observations: Clinical observation: convulsions,Endpoints: Observations: Clinical observation: salivation,Endpoints: Observations: Clinical observation: diarrhoea,Endpoints: Observations: Clinical observation: lethargy,Endpoints: Observations: Clinical observation: sleep,Endpoints: Observations: Clinical observation: coma,Endpoints: Observations: body weight ,Endpoints: Observations: food and water consumption,Endpoints: Observations: ophtalmological examination,Endpoints: Observations: organ weight and organ/body weight,Endpoints: Observations: rectal temperature,Endpoints: Observations: biomonitoring (urine/faeces collection),Endpoints: Observations: other,Endpoints: Lung function assessment: Lung burden: peo-1,Endpoints: Lung function assessment: Lung burden: peo-2,Endpoints: Lung function assessment: Lung burden: peo-3,Endpoints: Lung function assessment: Bronchoalveolar lavage (BAL): peo-1,Endpoints: Lung function assessment: Bronchoalveolar lavage (BAL): peo-2,Endpoints: Lung function assessment: Bronchoalveolar lavage (BAL): peo-3,Endpoints: Lung function assessment: Bronchoalveolar lavage (BAL): BALF: lactate dehydrogenase,Endpoints: Lung function assessment: Bronchoalveolar lavage (BAL): BALF: total protein or albumin,"Endpoints: Lung function assessment: Bronchoalveolar lavage (BAL): BALF: cell counts and differentials for alveolar macrophages, lymphocytes, neutrophils and eosinophils",Endpoints: Clinical pathology: Clinical chemistry: sodium,Endpoints: Clinical pathology: Clinical chemistry: potassium,Endpoints: Clinical pathology: Clinical chemistry: glucose ,Endpoints: Clinical pathology: Clinical chemistry: total cholesterol ,Endpoints: Clinical pathology: Clinical chemistry: creatinine,Endpoints: Clinical pathology: Clinical chemistry: blood urea nitrogen,Endpoints: Clinical pathology: Clinical chemistry: total protein ,Endpoints: Clinical pathology: Clinical chemistry: albumin,Endpoints: Clinical pathology: Clinical chemistry: alanine aminotransferase,Endpoints: Clinical pathology: Clinical chemistry: aspartate aminotransferase ,Endpoints: Clinical pathology: Clinical chemistry: alkaline phosphatase ,Endpoints: Clinical pathology: Clinical chemistry: chloride,Endpoints: Clinical pathology: Clinical chemistry: phosphorus,Endpoints: Clinical pathology: Clinical chemistry: calcium ,Endpoints: Clinical pathology: Clinical chemistry: globulin,Endpoints: Clinical pathology: Clinical chemistry: total bilirubin,Endpoints: Clinical pathology: Clinical chemistry: triglycerides,Endpoints: Clinical pathology: Clinical chemistry: other,Endpoints: Clinical pathology : Urinalysis: appearance (colour and turbidity),Endpoints: Clinical pathology : Urinalysis: volume,Endpoints: Clinical pathology : Urinalysis: osmolarity or specific gravity,Endpoints: Clinical pathology : Urinalysis: pH,Endpoints: Clinical pathology : Urinalysis: total protein ,Endpoints: Clinical pathology : Urinalysis: glucose ,Endpoints: Clinical pathology : Urinalysis: blood/blood cells,Endpoints: Clinical pathology: cholinesterase ,Endpoints: Clinical pathology: lipids,Endpoints: Clinical pathology: hormones,Endpoints: Clinical pathology: acid/base balance,Endpoints: Clinical pathology: methaemoglobin,Endpoints: Clinical pathology: heinz body,Endpoints: Clinical pathology: creatine kinase,Endpoints: Clinical pathology: bone marrow cytology ,Endpoints: Clinical pathology: troponins,Endpoints: Clinical pathology: lactate dehydrogenase,Endpoints: Clinical pathology: glutamate degydrogenase,Endpoints: Clinical pathology: gamma glutamyl transpeptidase ,Endpoints: Clinical pathology: Haematology: haematocrit ,Endpoints: Clinical pathology: Haematology: haemaglobin ,Endpoints: Clinical pathology: Haematology: mean corpuscular haemoglobin concentration,Endpoints: Clinical pathology: Haematology: mean corpuscular haemoglobin,Endpoints: Clinical pathology: Haematology: mean corpuscular volume,Endpoints: Clinical pathology: Haematology: erythrocyte count ,Endpoints: Clinical pathology: Haematology: total leucocyte count,Endpoints: Clinical pathology: Haematology: differential leukocyte count,Endpoints: Clinical pathology: Haematology: platelet count,Endpoints: Clinical pathology: Haematology: reticulocytes,Endpoints: Clinical pathology: Haematology: Clotting potential: prothrombin time,Endpoints: Clinical pathology: Haematology: Clotting potential: clotting time,Endpoints: Clinical pathology: Haematology: Clotting potential: partial thromboplastin time,Endpoints: Gross pathology: all gross lesion and masses,Endpoints: Gross pathology: liver ,Endpoints: Gross pathology: kidneys ,Endpoints: Gross pathology: adrenals ,Endpoints: Gross pathology: aorta,Endpoints: Gross pathology: bone marrow (and/or fresh aspirate),Endpoints: Gross pathology: testes,Endpoints: Gross pathology: lacrimal glands(extraorbital),Endpoints: Gross pathology: larynx (3 levels including the base of the epiglottis),Endpoints: Gross pathology: lungs  ( typically left lung including main bronchi and pleura although right lung could be used),"Endpoints: Gross pathology: lymph nodes from the hilar region of the lung ( especially for poorly soluble particulate test chemical), more in depth examination and/or studies with immunological focus ( additional draining lymph nodes my be considered, e.g; those from the posterior mediastinal, internal jugular, parathymicn posterior cervical, auricular, and/or cervical/submandibular regions, lymph nodes (distal from the portal-of-entry),",Endpoints: Gross pathology: mamary gland (male and female),Endpoints: Gross pathology: muscle (thigh),Endpoints: Gross pathology: nasopharyngeal tissues (at least 4 levels; 1 level to include the nasopharyngeal duct and the nasal associated lymphoid tissue (nalt),Endpoints: Gross pathology: oesophagus,Endpoints: Gross pathology: olfactory bulb,Endpoints: Gross pathology: pancreas,Endpoints: Gross pathology: parathyroids,"Endpoints: Gross pathology: peripheral nerve (sciatic or tibial, preferably close to muscle)",Endpoints: Gross pathology: pituitary,Endpoints: Gross pathology: prostate,Endpoints: Gross pathology: rectum,Endpoints: Gross pathology: salivary glands,Endpoints: Gross pathology: seminal vesicles,Endpoints: Gross pathology: skin,"Endpoints: Gross pathology: spinal cord (cervical, mid-thoracic, lumbar)",Endpoints: Gross pathology: sternum,Endpoints: Gross pathology: stomach ,Endpoints: Gross pathology: teeth,Endpoints: Gross pathology: thymus,Endpoints: Gross pathology: thyroid,Endpoints: Gross pathology: tongue,Endpoints: Gross pathology: trachea ,Endpoints: Gross pathology: ureter,Endpoints: Gross pathology: urethra,Endpoints: Gross pathology: urinary bladder ,Endpoints: Gross pathology: uterus,Endpoints: Gross pathology: other target organ,Endpoints: Gross pathology: vagina,Endpoints: Gross pathology: epididymides,Endpoints: Gross pathology: ovaries,Endpoints: Gross pathology: femur and stifle joint,Endpoints: Gross pathology: illeum,Endpoints: Gross pathology: spleen ,"Endpoints: Gross pathology: brain (including sections of cerebrum, cerebellum, and medulla/pons)",Endpoints: Gross pathology: caecum,Endpoints: Gross pathology: gallbladder,Endpoints: Gross pathology: heart ,Endpoints: Gross pathology: harderian glands,Endpoints: Gross pathology: coagulation glands,Endpoints: Gross pathology: jejunum,Endpoints: Gross pathology: colon,Endpoints: Gross pathology: duodenum,"Endpoints: Gross pathology: eye (retina, optic nerve) and eyelids",Endpoints: Histopathology: all gross lesion and masses,Endpoints: Histopathology: liver ,Endpoints: Histopathology: kidneys,Endpoints: Histopathology: adrenals ,Endpoints: Histopathology: aorta,Endpoints: Histopathology: bone marrow (and/or fresh aspirate),Endpoints: Histopathology: testes,Endpoints: Histopathology: lacrimal glands(extraorbital),Endpoints: Histopathology: larynx (3 levels including the base of the epiglottis),Endpoints: Histopathology: lungs  ( typically left lung including main bronchi and pleura although right lung could be used),"Endpoints: Histopathology: lymph nodes from the hilar region of the lung ( especially for poorly soluble particulate test chemical), more in depth examination and/or studies with immunological focus ( additional draining lymph nodes my be considered, e.g; those from the posterior mediastinal, internal jugular, parathymicn posterior cervical, auricular, and/or cervical/submandibular regions, lymph nodes (distal from the portal-of-entry),",Endpoints: Histopathology: mamary gland (male and female),Endpoints: Histopathology: muscle (thigh),Endpoints: Histopathology: nasopharyngeal tissues (at least 4 levels; 1 level to include the nasopharyngeal duct and the nasal associated lymphoid tissue (nalt),Endpoints: Histopathology: oesophagus,Endpoints: Histopathology: olfactory bulb,Endpoints: Histopathology: pancreas,Endpoints: Histopathology: parathyroids,"Endpoints: Histopathology: peripheral nerve  (sciatic or tibial, preferably close to muscle)",Endpoints: Histopathology: pituitary,Endpoints: Histopathology: prostate,Endpoints: Histopathology: rectum,Endpoints: Histopathology: salivary glands,Endpoints: Histopathology: seminal vesicles,Endpoints: Histopathology: skin,"Endpoints: Histopathology: spinal cord (cervical, mid-thoracic, lumbar)",Endpoints: Histopathology: sternum,Endpoints: Histopathology: stomach ,Endpoints: Histopathology: teeth,Endpoints: Histopathology: thymus,Endpoints: Histopathology: thyroid ,Endpoints: Histopathology: tongue,Endpoints: Histopathology: trachea ,Endpoints: Histopathology: ureter,Endpoints: Histopathology: urethra,Endpoints: Histopathology: urinary bladder ,Endpoints: Histopathology: uterus,Endpoints: Histopathology: other target organ,Endpoints: Histopathology: vagina,Endpoints: Histopathology: epididymides,Endpoints: Histopathology: ovaries,Endpoints: Histopathology: femur and stifle joint,Endpoints: Histopathology: illeum,Endpoints: Histopathology: spleen ,"Endpoints: Histopathology: brain (including sections of cerebrum, cerebellum, and medulla/pons)",Endpoints: Histopathology: caecum,Endpoints: Histopathology: gallbladder,Endpoints: Histopathology: heart ,Endpoints: Histopathology: harderian glands,Endpoints: Histopathology: coagulation glands,Endpoints: Histopathology: jejunum,Endpoints: Histopathology: colon,Endpoints: Histopathology: duodenum,"Endpoints: Histopathology: eye (retina, optic nerve) and eyelids",Endpoints: point of departure (pod) NOAEL,Endpoints: description of pod ,Endpoints: target organ,Endpoints: critical effect,Endpoints: moribund or dead animals prior to study termination,Endpoints: mortality rate,Endpoints: discussion and results,Endpoints: conclusion,Test method: Test substance: homogeneity and stability ,Test method: Test substance: treatment prior to application,Test method: Test substance: pH,"Test method: Test substance: physical form (gas, vapour, solid aerosol, liquid aerosol, mixture)",Test method: Test substance: particle count,Test method: Test substance: size distribution,Test method: Test substance: particle mass (mass median aerodynamic diameter mmad),Test method: Test substance: geometric standard deviation associated with mmad,Test method: Test substance: thermodynamic equivalent diameter for particles <100nm,Test method: Test substance: count median diameter (cmd),Test method: Test substance: geometric standard deviation associated with cmd,Test method: Test substance: fraction of particles ,Test method: Test substance: composition,Test method: Test substance: purity (%),Test method: Test substance: chemical batch nr,"Test method: Test substance: additional characterization (shape, surface area/specific surface area, surface chemistry, composition including coating and surface modifications, surface charge, particle solubility, and aggregation/agglomeration state",Test method: Test substance: additional info,Test method: Test substance: Vehicle: name,Test method: Test substance: Vehicle: concentration (%),Test method : Test condition: Test animal: species/strain,Test method : Test condition: Test animal: source,"Test method : Test condition: Test animal: age at start of experiment (days, weeks, months, years)","Test method : Test condition: Test animal: age unit (day, week, month, year)","Test method : Test condition: Test animal: sex (female, male)",Test method : Test condition: Test animal: housing and feeding,Test method : Test condition: Test animal: weight,"Test method : Test condition: Test animal: weight unit (gram, kilogram)",Test method : Test condition: Test animal: n animals / group,"Test method : Test condition: Test animal: pre-test conditioning or screening (diet, quarantine, ophthalmologic examination and treatment for disease)",Test method : Test condition: Test animal: number of satellite group,Test method : Test condition: nominal concentrations,Test method : Test condition: analytical concentrations,Test method : Test condition: dose level unit,"Test method : Test condition: repeated administration scheme (5days/week, 7days/week)","Test method : Test condition: Inhalation exposure: Inhalation chamber: nose-only, whole-body",Test method : Test condition: Inhalation exposure: Inhalation chamber: volume,Test method : Test condition: Inhalation exposure: Inhalation chamber: Flow: air flow rate,"Test method : Test condition: Inhalation exposure: Inhalation chamber: Flow: air flow rate/exposure port ( nose-only), or animal load /chamber (whole-body)",Test method : Test condition: Inhalation exposure: Inhalation chamber: source of air,Test method : Test condition: Inhalation exposure: Inhalation chamber: pressure difference,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: stability of exposure and generation of atmosphere,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: chamber equilibrium,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: temperature,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: humidity,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: particle-size,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: analystical concentration,Test method : Test condition: Inhalation exposure: Inhalation chamber: Equipment measuring: calibration of equipment,Test method : Test condition: Inhalation exposure: Inhalation chamber: location of sensors,Test method : Test condition: Inhalation exposure: Inhalation chamber: time to inhalation chamber equilibrium (t95),Test method : Test condition: Inhalation exposure: Inhalation chamber: treatment of air supplied/extracted,Test method : Test condition: Inhalation exposure: Inhalation chamber: number of volume changes per hour,Test method : Test condition: Inhalation exposure: duration of exposure (hour),Test method : Test condition: Inhalation exposure: degree of np agglomeration in the aerosol,Test method : Test condition: duration of exposure (28 days),Test method : Test condition: recovery period (day),Reliability: year,Reliability: GLP,Reliability: SCCS comment to test,Reliability: ref. in dossier,Reliability: limit test ,Reliability: range-finding study,Reliability: interim group,Reliability: control group ,Reliability: klimisch score,additional information,own comments
Phenoxyethanol,OECD 412,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/SCCS_o_195.pdf,,,"on exposure days, the clinical examination was performed before, during and after exposure. body weight and food consumption were determined at the start of the exposure period, on day 7 and on day 13. at study termination, clinical-pathological examinations of the blood, gross necropsy, measurement of organ weights and histopathological examinations of selected organs were conducted (liver, kidneys, adrenals, testes, thymus, spleen, lung).low inhalation toxicity, decreased body weight gain (females only) and food consumption (males and females) were observed in animals exposed to 1000 mg/m³ of 2-Phenoxyethanol. there were no treatment-related changes in clinical chemistry or haematology and no treatment related histopathological changes indicative of systemic toxicity. morphological changes such as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in the nasal cavity, larynx and lung in mid- and high-dose animals. lung weights were increased in mid- and high-dose males. ",decreased body weight gain and food consumption,34.4 ,noaec  mg/m3/day,"nasal cavity, larynx and lung ",,no,,the noaec for local effects in upper airways and lung was determined to be 48.2mg/m3/day ,,decreased body weight gain (females only),decreased food consumption (males and females),,lung weights were increased in mid- and high-dose males. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in larynx in mid- and high-dose animals.","as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and
minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in
the lung in mid- and high-dose animals.",,,,"as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and
minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in
the nasal cavity in mid- and high-dose animals.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,48.2,noaec mg/m3,,,no,,repeated inhalation exposure of rats to an aerosol coNTAining up to 1000 mg/m³ of 2- Phenoxyethanol for 6 hours per day for a total of 10 exposure days showed low inhalation toxicity. there were no treatment-related changes in clinical chemistry or haematology and no treatment related histopathological changes indicative of systemic toxicity,"the no-observed-adverse-effect concentration (noaec) for local effects in upper airways and lung was determined to be 48.2 mg/m3
.",,,,liquid aerosol,,,,,,,,,,> 99.9,41183068,,,air,,rat/wistar,,,,f & m,,,,10,,,"0, 40, 200, 1000","0, 48.2, 246, 1070",mg/m3,5 days/week,nose/head only,,,,,,,,,,,,,,,,,6,,14 d,,2007,yes,no data on lung lavage is available. the noaec derived should be multiplied with a factor of 5/7 in order to take into account the intermittent exposure (5 days a week). an adjusted noaec of 34.4 mg/m3/day may be used.,3,,,,a concurrent control group was exposed to conditioned air,2,,
"Decamethylcyclopentasiloxane (cyclopentasiloxane, D5)",,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/SCCS_o_174.pdf,"no behavioural abnormalities or mortalities were seen during the study. no effects were seen on mortality, body weight or body weight gain, food iNTAke, or clinical signs. urinalysis and biochemistry data indicated no changes of toxicological significance at termination of the treatment. however, a few minor changes with statistical significance were recorded in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm). an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only), increased incidence of goblet cell proliferation in the nasal cavity (males and females), and minimal to slight interstitial inflammation in the lungs (males and females) were observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ",,,,,,,,,,,,,,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm). an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only).  mean lung absolute weights and lung to brain weight ratios were significantly increased (<10%) in males and females at the highest dose.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was slightly decreased mean corpuscular haemoglobin concentration. there was no apparent relationship between these effects and the treatment.,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was a slightly increased mean corpuscular volume. there was no apparent relationship between these effects and the treatment.,,in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was a  slightly increased leukocyte and lymphocyte counts in males. there was no apparent relationship between these effects and the treatment.,,,,,,,,an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only) were observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ,,,,,,,,minimal to slight interstitial inflammation in the lungs (males and females) was observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ,,,,,,"increased incidence of goblet cell proliferation in the nasal cavity (males and females), was observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,results indicate repeated inhalation exposure to d5 induced an early non-sustained increase in liver weight and an early burst of hepatocellular hyperplasia and centrilobular hypertrophy in female rats exposed to concentrations of 160 ppm. ,"according to physicochemical specifications, 160 ppm is the highest D5 exposure concentration that can be reliably generated and maintained as a vapor without interference by aerosol formation",,,vapor,,,,,,,,,,,,,test substance: d5,,,rat/fischer 344,,,,f & m,,,,10,,,"0, 0.45, 0.66, 1.34, 2.29/3.71 ",,"mg /l (0, 28, 42, 96, 151/197 ppm)",5 days/week for 4 weeks. animals were exposed to the highest exposure concentration of 2.29 mg/l (151 ppm) for days 1 to 6 while the exposure to 3.71 mg/l (197 ppm) was for the remaining duration of the study (week 2 to 4). ,nose only,,,,,,,,,,,,,,,,,6,,28 days,,,,,38,,,,,,"SCCS conclusion on general toxicity: the SCCS has identified the liver as a potential target organ following repeated-dose oral exposure and liver, lungs and uterus as potential target organs following repeated-dose inhalation exposure. the effects observed on the liver were mainly an increase in liver weight. in the subchronic oral study (ref 45), this increase in liver weight was not accompanied by histopathological lesions and no biologically relevant alterations in enzymatic activities were observed. no liver effects were reported in the chronic inhalation toxicity/carcinogenicity study. therefore, the SCCS followed the hed guidance document on how to interpret hepatocellular hypertrophy (2002) and concluded that these liver effects are not adverse. therefore the oral dose of 100 mg/kg bw may be considered as a NOAEL. concerning exposure to d5 by inhalation, the inhaled concentration of 49 ppm was considered as a noaec.",
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,